INBP · XBRL financial data

Integrated Biopharma financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (INBP's year ends in late June)

In thousands of dollars	Q1 FY24Sep 30, 2023	Q2 FY24Dec 31, 2023	Q3 FY24Mar 31, 2024	Q4 FY24Jun 30, 2024	Q1 FY25Sep 30, 2024	Q2 FY25Dec 31, 2024	Q3 FY25Mar 31, 2025	Q4 FY25Jun 30, 2025	Q1 FY26Sep 30, 2025	Q2 FY26Dec 31, 2025	Q3 FY26Mar 31, 2026	Q4 FY26Jun 30, 2026
Cost of goods and services sold	12,083	10,989	11,899	11,462*	12,246	11,443	12,396	12,706*	11,670	11,251	10,383	9,768*
Gross profit	832	520	1,248	—	1,371	1,171	1,551	—	1,019	29	(276)	—
Selling, general and administrative	886	972	893	882*	881	969	812	880*	856	943	809	897*
Operating income (loss)	(54)	(452)	355	402*	490	202	739	589*	163	(914)	(1,085)	(869)*
Interest expense	(8)	(2)	4	58*	(14)	(11)	(5)	(9)*	(33)	(40)	(39)	124*
Other income (expense)	0	(2)	1	0*	—	(28)	34	(3)*	—	0	11	(23)*
Income tax expense (benefit)	13	(70)	67	146*	245	69	167	773*	73	(112)	(198)	516*
Net income (loss)	(59)	(382)	285	268*	259	116	611	(178)*	123	(762)	(837)	(1,366)*
Earnings per share, basic USD per share	0.00	(0.01)	0.01	0.01*	0.01	0.00	0.02	(0.01)*	0.00	(0.03)	(0.03)	(0.04)*
Earnings per share, diluted USD per share	0.00	(0.01)	0.01	0.01*	0.01	0.00	0.02	(0.01)*	0.00	(0.03)	(0.03)	(0.04)*
Weighted average shares, basic thousands of shares	29,966	30,100	30,100	30,100*	30,100	30,175	30,301	30,611*	31,060	31,060	31,060	31,060*
Weighted average shares, diluted thousands of shares	29,966	30,100	30,764	32,683*	30,650	31,303	31,515	31,214*	31,421	31,060	31,060	30,694*

Balance sheet

CSV

Fiscal quarters (INBP's year ends in late June)

In thousands of dollars	Q1 FY24Sep 30, 2023	Q2 FY24Dec 31, 2023	Q3 FY24Mar 31, 2024	Q4 FY24Jun 30, 2024	Q1 FY25Sep 30, 2024	Q2 FY25Dec 31, 2024	Q3 FY25Mar 31, 2025	Q4 FY25Jun 30, 2025	Q1 FY26Sep 30, 2025	Q2 FY26Dec 31, 2025	Q3 FY26Mar 31, 2026	Q4 FY26Jun 30, 2026
Cash and cash equivalents	2,594	732	2,020	1,677	2,271	2,461	2,961	3,615	4,732	5,314	5,826	4,471
Accounts receivable	4,172	3,733	4,719	4,668	4,385	4,228	5,080	5,430	3,983	3,592	3,655	3,334
Inventory	10,511	12,149	11,169	11,244	11,224	11,066	10,077	9,362	10,469	8,363	8,119	9,142
Total current assets	17,759	17,065	18,261	17,875	18,312	18,153	18,546	18,763	19,624	17,819	17,974	17,379
Property and equipment, net	1,636	1,558	1,891	1,885	1,853	1,771	1,811	1,723	1,819	1,765	1,697	1,754
Right-of-use asset	2,472	2,247	2,020	1,790	1,558	1,323	1,095	855	612	366	3,204	2,929
Total assets	26,642	25,721	26,942	26,207	26,183	25,661	25,656	24,901	25,540	23,547	26,669	25,338
Accounts payable	3,536	3,305	3,673	2,510	2,763	2,808	2,501	2,267	2,800	2,144	2,965	3,200
Current portion of long-term debt	—	—	18	—	—	—	—	—	—	—	—	—
Total current liabilities	6,197	5,833	6,945	6,123	6,029	5,575	4,981	4,248	4,764	3,541	5,527	5,802
Long-term debt	—	—	0	—	—	—	—	—	—	—	—	—
Lease liability, non-current	1,559	1,322	1,086	846	604	359	258	221	183	145	2,080	1,802
Total liabilities	7,756	7,155	8,031	6,969	6,633	5,934	5,273	4,584	5,051	3,778	7,687	7,671
Accumulated deficit	(32,398)	(32,780)	(32,495)	(32,227)	(31,968)	(31,852)	(31,241)	(31,419)	(31,296)	(32,058)	(32,895)	(34,261)
Total stockholders' equity	18,886	18,566	18,911	19,238	19,550	19,727	20,383	20,317	20,489	19,769	18,982	17,667
Total liabilities and equity	26,642	25,721	26,942	26,207	26,183	25,661	25,656	24,901	25,540	23,547	26,669	25,338
Common shares outstanding (cover page) thousands of shares	30,100	30,100	30,100	30,100	30,100	30,301	30,301	31,060	31,060	31,060	31,060	31,060

Cash flows

CSV

Fiscal quarters (INBP's year ends in late June)

In thousands of dollars	Q1 FY24Sep 30, 2023	Q2 FY24Dec 31, 2023	Q3 FY24Mar 31, 2024	Q4 FY24Jun 30, 2024	Q1 FY25Sep 30, 2024	Q2 FY25Dec 31, 2024	Q3 FY25Mar 31, 2025	Q4 FY25Jun 30, 2025	Q1 FY26Sep 30, 2025	Q2 FY26Dec 31, 2025	Q3 FY26Mar 31, 2026	Q4 FY26Jun 30, 2026
Net income (loss)	(59)	(382)	285	268*	259	116	611	(178)*	123	(762)	(837)	(1,366)*
Stock-based compensation	71	62*	60*	59*	53	43*	45*	44*	49	42*	50*	51*
Depreciation and amortization	77	78*	77*	87*	88	83*	76*	71*	77	78*	68*	70*
Net cash from operating activities	1,313	(1,827)*	1,643*	(186)*	657	201*	616*	591*	1,301	617*	517*	(1,194)*
Purchases of property and equipment	38	24*	345*	146*	56	29*	116*	(10)*	173	24*	0*	149*
Net cash from investing activities	(38)	(24)*	(345)*	(146)*	(56)	(29)*	(116)*	(4)*	(173)	(24)*	6*	(149)*
Net cash from financing activities	3	(11)*	(10)*	(11)*	(7)	18*	0*	67*	(11)	(11)*	(11)*	(12)*
Net change in cash	1,278	(1,862)*	1,288*	(343)*	594	190*	500*	654*	1,117	582*	512*	(1,355)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Integrated Biopharma	4,471	not reported	(1,194)*	31.1M	3.7 quarters	Q4 FY26 10-KJun 30, 2026
PTC Therapeutics	508,894	357,807	(25,311)*	83.5M	—	Q3 FY26 10-QSep 30, 2026
Inhibitor Therapeutics	516	not reported	(775)*	173.8M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Enveric Biosciences	8,296	not reported	(2,445)*	4.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Polomar Health Services	179	1,529	121*	28.4M	—	Q2 FY26 10-QJun 30, 2026
Q/C Technologies	308	not reported	(1,819)*	8.2M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Oragenics	3,864	not reported	(2,187)*	4.5M	1.8 quarters	Q2 FY26 10-QJun 30, 2026
Jaguar Health	3,788	1,225	(5,338)*	not reported	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Theriva Biologics	11,337	0*	(3,085)*	45.9M	3.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.